Hypothermic preservation is the standard of care for storing organs prior to transplantation. Endothelial and epithelial injury associated with hypothermic storage causes downstream graft injury and, as such, the choice of an ideal donor organ preservation solution remains controversiall.
Introduction
Improvements in immunosuppressive medications have allowed for better short-term outcomes in all aspects of solid organ transplantation. However, over the past two decades there have been few advances in the prevention of chronic transplant dysfunction (CTD). CTD remains a leading cause of gra loss in the long term and many of its effects can be traced back to the initial oxidative and immunological insults accrued during early ischemia reperfusion injury to endothelial and epithelial cells post-reperfusion.
Central to these immunological insults is the activation of donor cells that, upon brain death, organ procurement, organ preservation, and reperfusion, promotes inammation, cytokine and chemokine release and is central to the programming of recipient immune cells. It is appreciated that modulation of the endothelium prior to transplantation may improve gra outcomes. 3, 4 Recent studies have shown that treatment of endothelial cells (ECs) in vitro with the mTOR inhibitor rapamycin, an immunosuppressive drug used clinically, can render ECs tolerogenic.
5 Pre-treatment of ECs with rapamycin reduced proliferation of allo-reactive memory T cells, cytokine production, and EC activation. Pre-treatment further promoted the differentiation of T regulatory cells in an EC/T cell co-culture system. 3, [5] [6] [7] These elegant studies demonstrate that pre-injury rapamycin therapy provides protection from EC-mediated immune injury. Furthermore, in in vivo studies, human aortic gras were transplanted into immunodecient SCID/beige mice and gras were allowed to "heal-in" for 30 days, aer which, mice were treated with rapamycin for 3 days. 5 Gras were then harvested and re-transplanted into humanized SCID/beige mice. Gras from rapamycin pre-treated donors were signi-cantly protected from gra injury and chronic rejection, as compared to untreated controls. 5 The conclusion from these studies was that rapamycin-modulated donor ECs allowed for protection against the development of CTD by reprogramming their ability to present antigen and blunt initial responses to injury post-reperfusion. Although rapamycin has been touted to confer a protective and tolerogenic phenotype to transplant recipients, its use in the perioperative period is hindered by the drug's numerous systemic side effects. 8 However, given its clinical promise, strategies that provide a platform to facilitate donor rapamycin delivery in a relevant time frame are necessary if these results are to be translated clinically.
9,10
Here, we capitalized on these unique ndings and have developed a bioengineered solution delivering rapamycin to the donor organ prior to transplantation, by the addition of Targeted Rapamycin Micelles (TRaM) to standard organ preservation solution. Micellar nanoparticles (NPs) are ideal vehicles for therapeutics due to their small size and hydrophobic core allowing for self-assembly with hydrophobic payloads such as rapamycin. Additionally, micellar constructs facilitate the application of surface targeting moieties that can be tailored to promote uptake by specic cell types or under specic physiochemical conditions. To this end, we have previously designed, constructed, and characterized rapamycin micelles decorated with cyclic arginine-glycine-aspartate moieties (cRGD) specic for alpha V beta 3 (aVb3) integrins located on the surface of endothelial and epithelial cells. Although aVb3 integrin molecules are not specic for endothelial or epithelial cells, using these TRaMs, we demonstrated that membrane targeting facilitated receptor-mediated endocytosis and signicantly enhanced micelle-specic uptake as compared to untargeted constructs in in vitro models. 11 Further, we have shown that
TRaMs inhibit EC cytokine production and alloreactive T cell proliferation, as compared to free rapamycin or untargeted rapamycin micelles, in in vitro models.
11
Most transplanted organs in the United States are procured from deceased donors, and as such, the organ must be cold stored for a signicant period of time until it can be transplanted into a suitable recipient. Various preservation solutions exist, each substantially different in their composition, but the purpose of each are similar: to prevent cellular edema, delay cell destruction, maintain organ metabolic potential, and maximize organ function aer perfusion is re-established. They do nothing to modulate the immunologic injury suffered as a consequence of organ donation nor do they prepare the donor organ for the oncoming immunological attack by the recipient's immune system. This necessary step in the transplantation process provides a window of opportunity to deliver therapeutics directly to the vascular endothelia, and/or the respiratory epithelia of the donor organs ex vivo as an additive to a standard preservative such as University of Wisconsin (UW) solution.
Therefore, in this study, we report the application of our novel TRaM nanoparticles as an additive to UW and explore the impact of donor organ nanoparticle delivered rapamycin on the development of chronic rejection.
11 For the rst time, we show that donor organ pre-treatment with TRaM augmented UW preservation solution, as compared to standard-of-care UW alone and UW augmented with free rapamycin, protects against the development of chronic rejection in two separate in vivo allogra models.
Methodology

Preparation of micelles
Micelle encapsulation of rapamycin (RaM) was carried out as described by Nadig et al. 11 Rapamycin was mixed with amino-PEG-PE 1,2-diacyl-sn-glycero-3-phosphoethanolamine-N-[amino-poly(ethylene glycol)] and PHC (N-palmitoyl homocysteine (ammonium salt)), suspended in chloroform. The chloroform mixture was sonicated then the solvent was evaporated in a vacuum oven at room temperature. The pellet obtained aer evaporation was heated to 80 C and dissolved in nanopure water to produce amine-functionalized micelles. The micelle solution was sonicated in a water bath and ltered to remove aggregates. For the synthesis of TRaM, the RaM solution was used for peptide conjugation (1 : 1 ratio of carboxyl group on peptide to amine group on the micelles at 30% coverage of amines). cRGD was added to MES buffer (pH 4.5) in separate scintillation vials followed by EDC and sulfo-NHS. PBS (pH $12) was added to bring the pH back to 7.5. The micelle solution was added to the peptide solution and incubated at room temperature. Excess peptide was removed using 10 K MWCO ultracentrifugal device (Millipore, MD). For dye labelling, NHS Dylight 680 was added at a ratio covering 30% amine groups of the micelles to RaM and TRaM, respectively. Excess dye was removed using 10 K MWCO ultracentrifugal device. In order to assess the quality of micelles and obtain quantitative measures that allow comparison between different batches of micelles, various parameters are monitored. For micelles used in analytical and bioanalytical applications, the main characteristics include the average diameter and degree of size polydispersity; encapsulation efficiency; the ratio of phospholipids to encapsulant concentration; lamellarity determination. Small batch-to-batch variations in the amine-PEG-PE and PHC ratio resulted in small differences in their physical parameters. For experimental purposes, only batches with >95% similarity were used.
HPLC analysis of rapamycin encapsulation in micelles
Analysis of standard rapamycin and rapamycin in micelle samples were performed with a Dionex UltiMate3000 chromatograph (Thermo Scientic) equipped with a UV-visible detector and an auto sampler as described with minor modi-cations. 12, 13 Rapamycin was separated on a C18 reverse phase analytical column (250 mm Â 4.6 mm 5 micron particles) under isocratic condition. The mobile phase was a mixture of acetonitrile and water in the ratio 98 : 2 (v/v). The ow rate was 1 mL per minutes and rapamycin was monitored at 278 nm with retention time of 4.8 minutes at 21 C.
Hypoxic cold storage models of ischemia-reperfusion injury 
In vitro analysis of mTOR inhibition
To assess the efficacy of TRaM and free rapamycin on inhibiting MCEC mTOR activity, MCECs were again exposed to simulated cold hypoxic reperfusion injury, using the model outlined above. In these experiments, UW solution was augmented with TRaM, empty micelles, free rapamycin, or DMSO vehicle. Following 6, 12, 18, 24, or 72 hours of reperfusion, MCEC protein lysates were collected and analyzed by western blot as previously described.
14 Briey, cells were washed, detached mechanically, pelleted and lysed with M-PER Mammalian Protein Extraction Reagent (Thermo Fisher Scientic, MA) that contained 1Â phosphatase and 1Â protease cocktail inhibitors (Thermo Fisher Scientic, MA). Aer quantication, proteins were denatured and separated using 4-20% gradient SDS-PAGE (Bio-Rad Laboratories, CA), followed by wet transfer to a PVDF membrane (Bio-Rad Laboratories, CA) for immunoblotting. Primary antibodies against P-p70S6K (Thr389), p70S6K (all from Cell Signaling, MA), beta actin (Santa Cruz, TX) were used at a 1 : 1000 dilution. Secondary antibodies conjugated to horseradish peroxidase (GE Healthcare, Little Chalfont, UK) were used at a 1 : 2000 dilution. Signal was determined by chemiluminescence using lm development and digital imaging methodologies. Quantication of band intensity was performed using ImageJ v1.46 (NIH, MD).
In vitro and ex vivo uptake of nanoparticles
We have previously demonstrated the uptake of TRaMs in MCECs and aortas, and thus here the in vitro and ex vivo uptake of TRaMs was assessed in human bronchial epithelial cells (BEAS-2B) and mouse trachea. 11 For in vitro experiments BEAS-2B cells were exposed to simulated cold hyperoxic storage and reperfusion as previously described. 15 Cells were exposed to UW or UW augmented with TRaM and following 18 hours of cold storage, were reperfused for 10 and 60 minutes to visualize TRaM internalization using Olympus Fluoview FV10i LIV Confocal Microscope (Olympus, NC). Donor tracheas were harvested for analysis of ex vivo delivery of NPs. Tissue segments were stored on ice for 6 hours in UW solution, or UW solution augmented with increasing doses of RaM and TRaM (100, 500, and 1000 ng mL
À1
). Fluorescence multispectral imaging was performed using the Maestro Imaging System (PerkinElmer, MA). Multispectral images were acquired under a constant exposure of 2000 ms with an orange lter acquisition setting of 630-850 nm in 2 nm increments. Multispectral images were unmixed into their component spectra (Dylight 680, autouorescence, and background) and these component images were used to gain quantitative information in terms of average uorescence intensity by creating regions of interest (ROIs) around the organs in the Dylight 680 component images. Male Balb/c and C57BL/6 mice (8-12 weeks) were obtained from Jackson Laboratory (Bar Habor, ME). All mice used for transplantation studies weighed 20-30 g and were housed under specic pathogen free conditions at MUSC. For all surgical procedures, mice were anesthetized with intraperitoneal injections of ketamine (75 mg kg À1 ; Lloyd Laboratories, IA) and xylazine (16 mg kg À1 ; Vedco, Inc., MO).
Animals
Tracheal transplantation
Orthotopic tracheal transplants were performed as previously described. 16, 17 Balb/c donor trachea, 6-8 tracheal ring segments, were excising and stored in either control UW solution or treatment groups consisting of TRaM, RaM, free rapamycin, or empty micelles at 1000 ng mL À1 . All donor tracheas were stored in their respective solutions for 4 hours on ice prior to transplantation into allogeneic C57Bl/6 recipients. Tracheal gras were excised on days 7 and 28 days post transplantation for analysis.
Aorta transplantation
Balb/c donor mice were anesthetized and infrarenal aorta isolated and cuffs secured at both ends with 10-0 nylon suture (AROSurgical Instruments Corporation, Newport Beach, CA). The donor aorta were then stored on ice in University of Wisconsin (UW) solution alone (Bridge to Life Ltd, SC), or UW augmented with either TRaM, RaM, free rapamycin, or empty micelles at dose of either 100 or 1000 ng mL À1 . All donor aortas were stored in their respective solutions for 6 hours prior to transplantation in C57Bl/6 allogeneic recipients.
Transplantations were performed as previously described using a modied-cuff technique 18 and gras harvested 28 days post transplantation.
Histopathology
Allogras were harvested at post-operative days 7 or 28 and tissue segments were embedded in paraffin. Six mm thick aorta or trachea sections were stained with hematoxylin and eosin and Elastin-van Gieson stain (EvG, HT25; Sigma, MO). Morphometric analysis of transplant arteriosclerosis on EvG stained sections was measured as described. 19 Tracheal gra injury and remodeling was determined as previously described. 20 
Statistical analysis
All data are expressed as mean +/À SD. All data analysis was performed using GraphPad Prism soware version 6 (La Jolla, CA) unless specied. Multiple variables were analyzed via analysis of variance techniques, and a p value < 0.05 was considered statistically signicant.
Results
Rapamycin exhibits improved immunosuppressive capacity when compared to current standard-of-care regimens
In order to establish the superiority of mTOR inhibition over standard-of-care immunosuppressants, we performed a head-tohead comparison of rapamycin to cyclosporine (CSA), FK506 (tacrolimus; TAC), and mycophenolate mofetil (MMF). Using mouse keratinocyte chemoattractant (KC), a surrogate for IL-8 in the murine system and a potent inammatory cytokine of ECs and epithelial cells, as a readout. ELISAs were performed in a dose-escalating manner with no drug and vehicle as controls. Rapamycin reduced levels of EC released mouse KC across three varying doses and signicantly suppressed KC levels when compared to MMF and TAC at 1, 10 and 100 ng mL
À1
, respectively (Fig. 1a ). All immunosuppressives were tested for their toxicity prole against mouse ECs and no signicant toxicity was noted across each of these doses (Fig. 1b) .
Preconditioning MCECs with rapamycin inhibits mTORC1 activity
We utilized a novel in vitro system of ischemia reperfusion wherein mouse cardiac ECs (MCEC) were subjected to cold ischemia (hypoxic chamber) for 6 hours in UW solution alone or UW solution augmented with 100 ng mL À1 free rapamycin.
Following the ischemic insult, the cells were reperfused with warm media to mimic reperfusion. EC lysates were obtained at specic post-reperfusion time points and ribosomal protein S6 kinase beta-1 or P-p70S6K (Thr389) detected by western blotting to determine mTOR activation as the phosphorylation of this ribosomal protein at threonine 389 is a well-described marker for activation by mTOR.
In rapamycin treated cells, P-p70S6K is completely absent at 6, 12, 18, and 24 hours post-reperfusion indicating pretreatment maintains its inhibitory effects 24 hours postreperfusion ( Fig. 2a and b) . When rapamycin was added aer Band intensity was normalized to beta-actin. Another group of MCECs was subjected to hypoxic cold storage for 6 hours in standard UW solution, followed by warm reperfusion with media augmented with 100 ng mL À1 rapamycin for 6, 12 or 24 hours. Whole cell lysates were obtained and immunoblotted as above. (c) P-p70S6K is completely absent at 6, 12, and 24 hours post-reperfusion in both scenarios of rapamycin treatment during or after cold storage. (d) Band intensity of the representative immunoblot normalized to beta-actin.
cold storage upon reperfusion in warm media for 6, 12, 18, 24 hours P-p70S6K remained absent (Fig. 2c and d) .
Bioengineering rapamycin micelles
Micelles encapsulating rapamycin, both untargeted (RaM) and targeted (TRaM), were prepared as previously described.
11 TRaM are relatively monodisperse and measure 15.3 nm +/À 2.3 nm (PDI 0.03). Encapsulation efficiency (EE) is approximately 42% and the zeta potential is measured as À40.64 +/À 3.93 mV. The micelles are relatively stable under various physiological conditions, including buffered solutions and serum containing solutions. Over time, only 20-26% of the encapsulated rapamycin leaches from the micelles.
Reverse phase-high liquid chromatography (RP-HPLC) was used to analyze solubilized rapamycin in the phospholipidbased vehicle.
12,13 Separation was performed on a C18 column reverse phase analytical column under isocratic conditions with a mixture of acetonitrile and water as the mobile phase. The separation process resulted in reasonable retention times and successful separation of the analytes (Fig. 3a, c and d) .
Encapsulation efficiency of rapamycin was calculated at approximately 42% within the micelles. Linearity of the method was conrmed by preparing rapamycin standard curves for the analytical range of 125-2000 ng mL À1 (Fig. 3b) . Statistical analysis using least square regression (r 2 $ 0.99) conrmed linearity for rapamycin for all standard curves.
Functional doses of rapamycin and TRaM nanotherapy inhibit mTORC1 activity equally in MCEC
Utilizing the same in vitro model of ischemia reperfusion, we compared MCEC subjected to cold ischemia for 6 hours in standard UW solution or UW solution augmented with free rapamycin at 1000 ng mL
À1
, TRaM nanotherapy at 1/10 of the dose of free rapamycin (100 ng mL À1 ), and empty micelles with no payloads. MCEC were then reperfused with warm media in standard fashion. Whole cell lysates were obtained at 24 and 72 hours post-reperfusion and immunoblotting was performed to detect P-p70S6K (Thr389). TRaM nanotherapy signicantly inhibited the activation of mTOR complexes signied by an absence of phosphorylated P70S6K (Fig. 4) .
TRaM-enhanced UW solution allows for nanoparticle uptake in normoxic and cold hyperoxic environments and dampens the inammatory cytokine response
We have previously shown that TRaM are taken up under cold hypoxic conditions by receptor-mediated endocytosis 11 in MCECs, and therefore in order to verify the clinical relevance of the TRaM nanotherapy in lung transplantation, human bronchial epithelial cells were used (BEAS-2B) to interrogate TRaM uptake in cold hyperoxic environments (i.e. cold preservation in inated lungs) as compared to normothermic, normoxic environments.
Here, we subjected human BEAS-2b cells to 4 C and 100% oxygen environments for 6 hours and then reperfused the cells with warm UW with or without TRaM. Pre-reperfusion the TRaM is isolated to the membrane and proceeds to enter the cells over a period of 60 minutes post-reperfusion (Fig. 5a ). BEAS-2B cells were subjected to cold hyperoxia, for 18 hours in standard UW solution or UW solution augmented with the following treatment groups: TRaM, free rapamycin, empty micelles, vehicle, and normal BEAS-2b cells. Following cold storage, the cells were ) and rapamycin (1000 ng mL À1 ) were assessed. MCECs were subjected to hypoxic cold storage for 6 hours in standard UW solution or UW solution augmented with TRaM, free rapamycin, empty micelles, or DMSO vehicle, followed by warm reperfusion with culture media. Whole cell lysates were obtained at 24 or 72 hours post-reperfusion, and immunoblotting was performed to detect P-p70S6K (Thr389). . BEAS-2B cells were subjected to hyperoxic cold storage for 18 hours in standard UW solution or UW solution augmented with 100 ng mL À1 TRaM, 100 ng mL À1 free rapamycin, 100 ng mL À1 empty micelles, or DMSO vehicle, following which the cells were reperfused with warm media. Whole cell lysates were obtained at specific post-reperfusion time points, and P-p70S6K (Thr389) detected by western blot. (b) A representative immunoblot indicating P-p70S6K is completely absent at 24 hours post-reperfusion and (c) band intensity of the representative immunoblot normalized to beta-actin, (d) significant decrease in IL-8 production in rapamycin or TRaM treated BEAS-2b cells compared to those stored in UW alone. reperfused with warm media and cell lysates obtained at 24 hours post-reperfusion. In keeping with our ndings with MCECs ( Fig. 4) , P-p70S6K (Thr389) expression was attenuated by TRaM cold storage preconditioning 24 hours post-reperfusion ( Fig. 5b  and c) . Furthermore, TRaM pre-treatment was associated with a dampening in epithelial cell inammation as measured by IL-8 secretion, a key modulator of immune cell migration and activation post lung transplantation (Fig. 5d) .
TRaM uptake in tracheal tissues
To directly visualize the ex vivo uptake of TRaM, we administered increasing concentrations of Alexa uor-680 labelled micelles (TRaM, RaM, and empty) in UW solution to murine tracheas and cold stored them for 6 hours. Following rinsing with UW solution, the tracheas were imaged (Fig. 6a) . The ex vivo uorescent signals increased in a dose and time dependent manner for both RaM and TRaM (Fig. 6b) , with cRGD targeted Fig. 7 TRaM pre-treated tracheal allografts after transplantation. (a) Tracheal allografts stored in UW solution alone or UW augmented with 1000 ng mL À1 of free rapamycin, or 100 ng mL À1 of TRaM were transplanted and procured at 7 days (a) or 28 days (b) after implantation. Epithelial/ lamina propria ratios (c) and pathologic scores (d) of fibrosis revealed significant protection from fibrotic scarring in trachea treated with TRaM when compared to UW alone or 10-fold more free drug. **p < 0.05; TRaM resulting in greater micelle uptake as compared to RaM or empty micelles with a 3-fold higher uorescence noted.
Overall, these results demonstrate that micelles can successfully accumulate within the trachea during ex vivo cold storage.
Pre-treatment with TRaM-enhanced UW solution prevents brosis in orthotopic tracheal allogras
Utilizing the orthotopic tracheal transplant model as an established microsurgical surrogate for lung transplantation, tracheas were procured from Balb/c mice, and stored in UW solution alone, or UW solution augmented with 1000 ng mL
À1
of rapamycin, or 100 ng mL À1 TRaM for 4 hours prior to orthotopic transplantation into fully allogeneic C57/BL6 recipients. Gras were procured at 7 days (Fig. 7a ) and 28 days (Fig. 7b) . At both time points, the epithelial to lamina propria ratio and pathological brotic score revealed that TRaM-treated tracheas had minimal evidence of disease pathology and were similar to isogras when compared to those tracheas stored in UW solution alone or augmented with free rapamycin (Fig. 7c  and d ). Of note, recipients of donor trachea cold stored in 1000 ng mL À1 of free rapamycin had an increase incidence of fatal tracheal dehiscence in 6 of 12 transplanted mice. No dehiscence was observed in UW alone or UW solution augmented with TRaM.
Pre-treatment with TRaM enhanced UW solution prevents allogra vasculopathy in aortic interposition allogras
The hallmark pathology of chronic gra rejection is represented by the bro-proliferative lesions that occur in the vessels supplying and within organ allogras. We performed aortic interposition gras between Balb/c donors to completely allogeneic C57/BL6 mice. Mouse aortas were cold stored in UW solution alone or augmented with 100 or 1000 ng mL À1 of free rapamycin or 10 or 100 ng mL À1 of TRaM for 6 hours. Aortas were transplanted between syngeneic C57/BL6 mice as isogra controls. Twenty-eight days aer transplantation, the aortas were procured and H&E and Elastin van Gieson (EvG) staining performed to determine the degree of vasculopathy using previously established formulas.
21
Animals in the UW solution alone and free drug groups exhibited marked amounts of vasculopathy ( Fig. 8a and b) . In contrast, a single dose of TRaM at 1/10 (100 ng mL À1 ) the dose of highest free drug added to UW solution signicantly abrogated vasculopathy, with intimal thickening not dissimilar to that seen in isogra controls. However, to conrm its therapeutic nature when doses of TRaM were reduced a further 10-fold, the therapeutic effect was lost supporting the dosedependent nature of the nanotherapy.
Discussion
Solid organ allogra survival in the short-term has improved, however success in achieving long-term survival remains elusive. There is growing appreciation that factors occurring early in the life of the gra may affect late outcomes. Expanding evidence suggests that blunting the immunologic activation of donor antigen presenting cells, such as endothelial and epithelial cells, prior to or aer transplantation may be the key to downregulating early inammatory processes which leads to downstream gra loss. [22] [23] [24] To that end, we have devised a novel nanoparticle that, via a targeting moiety, facilitates nanoparticle uptake in endothelial and epithelial cells in vitro and in vivo. Using these unique characteristics we are able to deliver therapeutic payloads ex vivo and "pre-treat" organs prior to the onslaught of ischemia/reperfusion injury. The prevention of chronic rejection by rapamycin at 1/10 the dose of free drug when encapsulated into a micellar nanoparticle further allows for impactful clinical translation given the host of systemic clinical adverse effects caused by the drug in its current form. In these novel studies, we investigated the efficacy of targeted rapamycin nanotherapy in vitro and then applied it to an in vivo system mimicking bronchial brosis in lung transplantation and transplant arteriosclerosis, the hallmark vascular lesion of chronic transplant dysfunction in all solid organ transplants.
Various studies suggest that systemic delivery of nanoparticles and emulsions containing chemotherapeutics concentrated in a transplanted heart can prevent vasculopathy. 25, 26 Yet others advocate for the use of nanoparticles decorated with immunotherapeutics as a delivery device for tissues such as allo-islets to allow for implantation under the shield of immunomodulating therapeutics.
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Pharmacotheapeutic delivery of immunosuppressants via micro and nanoparticles have been touted to represent the "next era" of transplantation, as increased doses of drug may be delivered directly to the area of need. Yet, to date, studies investigating the use of NPs in transplantation have largely revolved around systemic delivery with increased concentration in the graed tissues and not on treatment of the donor organ themselves before transplant. Although manipulation of donor organs prior to transplantation is not currently the standard-of-care and represents a paradigm shi in transplantation, pre-treatment strategies may be the key to unlocking the early problems that lead to late gra loss. Along with pre-treatment strategies, delivery mechanisms intended to allow for organ level immunosuppression while leaving the patient's global immune system intact may represent the future of organ specic immunosuppression. These disruptive technologies include micro and nanoparticles carrying immunosuppressants and chemotherapeutics, for example, delivered both systemically and directly to an organ allogra. 25, 26, 28 In the studies presented here, we utilized rapamycin as it has been previously shown that rapamycin not only prevents the development of vasculopathy, but is implicated in the induction of tolerance, and maintains a hydrophobic chemical composition allowing it to serve as the core of the micelle. In addition, despite the immunologic advantages of the drug, rapamycin is seldom used in the perioperative period due to its deleterious systemic side effect prole. Investigations wherein human arterial segments transplanted as aortic allogras in rapamycintreated mice inoculated with allogeneic PBMC are resected and re-transplanted into other humanized mice, revealed an abrogation of T-cell mediated vasculopathy, further attesting to the drug's unique immunologic advantage. 5 Although elegant, these studies are not readily translated to the clinic as the "donor" would require rapamycin pre-treatment. However, the effects of rapamycin on decreasing the interferon gamma axis and inhibiting the proliferation of vascular smooth muscle cells and recruitment of effector T cells by up-regulating inhibitory co-stimulation molecules on ECs, such as PDL-1 and PDL2, can be maintained by a local delivery method of targeted rapamycin. 29 Rapamycin pre-treatment of ECs has also been shown to reduce EC activation, proliferation of alloreactive memory T cells, and allow for the selective proliferation of gra protective T regulatory cells, in vitro and in vivo. 5, 29, 30 In addition, these studies also established that rapamycin signicantly reduces the secretion of IL-6. 5 The ability of nano-based targeting of small interfering RNA (siRNA) to disrupt EC MHC expression and thereby reduce recruitment and activation in T cells in the setting of transplantation has also been successfully explored and bolsters the idea that pre-treatment in this setting may prevent long term dysfunction. 4 Taken together, these data support the use of rapamycin encapsulated as a targeted nanotherapeutic micelle to abrogate transplant brosis and vasculopathy when used as a donor organ preservation pretreatment strategy. In a recent study by Solhjou et al., novel controlled-release IL-6-containing nanoparticles were utilized as a pre-treatment method in experimental cardiac allogras to blunt early IRI injury and chronic rejection responses. 31 In the novel studies presented here, we approach the problem of vasculopathy in a similar fashion in the preservation phase of transplantation prior to implantation of the allogra.
Conclusions
Here, for the rst time, we demonstrate that delivery of rapamycin-encapsulated nanotherapy directly to allogra epithelial cells and ECs can prevent downstream organ dysfunction and improve cellular health in vitro while preventing vascular lesions and brosis of chronic rejection in vivo when compared to freely delivered rapamycin. In fact, high doses (1000 ng mL À1 ) of free rapamycin dissolved in the preservation solution resulted in an increase incidence of fatal tracheal dehiscence in our mouse model lung transplantation. We did not see this in the aortic interposition gra model, probably due to our use of a previously described cuffed anastomosis. 18 The two separate models of transplantation provide proof-of-principle for rapamycin's clinical potential in donor organ pre-treatment. Therefore, inclusion of the FDA-approved rapamycin, in the form of a novel targeted nanotherapeutic micelle, can protect allogras from endothelial and epithelial activation, signicantly reducing organ damage and potentially inducing a tolerogenic gra microenvironment. 
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